Oncolytic MG1-MAGEA3 With Ad-MAGEA3 Vaccine in Combination With Pembrolizumab for Non-Small Cell Lung Cancer Patients
Clinical trial NCT02879760 · COMPLETED
Trial details
- NCT number
- NCT02879760
- Sponsor
- Turnstone Biologics, Corp.
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-03-08
- Primary completion
- 2020-02-15
- Enrollment
- 16
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.